嚴重肢體缺血治療 (CLI) 市場、機會、成長動力、產業趨勢分析與預測，2024-2032 年

Critical Limb Ischemia Treatment (CLI) Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月01日 | 出版商:

Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球危重肢體缺血 (CLI) 治療市場預計 2023 年將價值 42 億美元，2024 年至 2032 年複合年成長率為 6.7%。疼痛、潰瘍和潛在的截肢。由於醫療技術的進步，血管重建手術的結果有所改善，在恢復血流和避免肢體喪失方面發揮關鍵作用。

此外，血管影像技術的進步提高了診斷 CLI 和規劃血管重建的精確度。雙功超音波、電腦斷層血管攝影 (CTA) 和 MRI 系統等工具可提供複雜的血管影像，這對於評估阻塞嚴重程度和位置至關重要。這些增強的診斷不僅簡化了治療，也提高了患者的治療效果。

整個嚴重肢體缺血治療產業根據治療類型、最終用途和地區進行分類。

該市場按治療類型細分，包括手術、藥物和其他治療。手術領域佔據市場主導地位，到2023 年估值將達到29 億美元。防止肢體喪失和改善預後至關重要。

CLI 治療產業的最終用途細分包括醫院、門診手術中心等。預計到 2032 年，醫院領域將以 7% 的複合年成長率成長。他們提供全方位的護理，從診斷和影像到手術和術後護理。先進的影像工具，包括雙功能超音波和 CT 血管造影，使醫院能夠準確測量動脈阻塞並制定合適的治療計劃。

2023 年，北美 CLI 治療市場價值為 17 億美元。該地區與 CLI 相關的危險因子（例如糖尿病和高血壓）盛行率升高，刺激了從藥物治療到手術介入等多種治療選擇的強烈需求。

產業生態系統分析
產業影響力
- 成長動力
  - 周邊動脈疾病（PAD）盛行率增加
  - 血管重建手術的技術進步
  - 提高認知和早期診斷
- 產業陷阱與挑戰
  - 先進治療費用高
成長潛力分析
技術景觀
未來市場趨勢
監管環境
產品管道分析
報銷場景
波特的分析
差距分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按治療類型，2021 - 2032 年

主要趨勢
程式
- 血管內手術
  - 血管成形術
  - 支架置入術
  - 旋切術
- 手術程序
  - 繞道手術
  - 動脈內膜切除術
藥物
- 抗血小板藥物
- 抗凝血劑
- 降膽固醇藥物
- 止痛藥
- 其他藥物
其他治療類型

第 6 章：市場估計與預測：按最終用途分類，2021 - 2032 年

主要趨勢
醫院
門診手術中心
其他最終用戶

第 7 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 8 章：公司簡介

Abbott Laboratories
Bayer
Boston Scientific
Cesca Therapeutics
Cook Medical
Eli Lilly and Company
Medtronic plc
Micro Medical Solutions
Pfizer
Sanofi
Terumo Corporation
Teva Pharmaceuticals

簡介目錄

Product Code: 10560

The Global Critical Limb Ischemia (CLI) Treatment Market, valued at USD 4.2 billion in 2023, is set to grow at a CAGR of 6.7% from 2024 to 2032. CLI, a severe manifestation of peripheral artery disease, restricts blood flow to the limbs, leading to pain, ulcers, and potential limb amputation. Due to advancements in medical technology, revascularization procedures have seen improved outcomes, playing a pivotal role in restoring blood flow and averting limb loss.

Moreover, advancements in vascular imaging technologies have sharpened the precision in diagnosing CLI and planning revascularization. Tools, such as duplex ultrasound, computed tomography angiography (CTA), and MRI systems provide intricate vascular images, crucial for assessing blockage severity and location. These enhanced diagnostics not only streamline treatment but also elevate patient outcomes.

The overall critical limb ischemia treatment industry is categorized based on treatment type, end-use, and region.

The market, segmented by treatment type, includes procedures, medications, and other treatments. Dominating the market, the procedures segment was valued at USD 2.9 billion in 2023. Encompassing revascularization techniques like angioplasty, stent placement, atherectomy, and surgical bypass, this segment is vital for restoring blood flow in CLI patients, preventing limb loss, and enhancing outcomes.

End-use segmentation of the CLI treatment industry includes hospitals, ambulatory surgical centers, and others. The hospitals segment is projected to grow at a 7% CAGR through 2032. As primary venues for CLI diagnosis and treatment, hospitals cater to the complexities of this severe peripheral artery disease. They provide a full spectrum of care, from diagnosis and imaging to surgical and post-operative care. Advanced imaging tools, including duplex ultrasound and CT angiography, empower hospitals to gauge arterial blockages accurately and devise suitable treatment plans.

North America CLI treatment market was valued at USD 1.7 billion in 2023. North America's leadership in the global CLI treatment arena is underscored by its advanced healthcare system, ensuring widespread access to cutting-edge diagnostic and therapeutic tools. The region's heightened prevalence of CLI-related risk factors, such as diabetes and hypertension, fuels a strong demand for diverse treatment options, spanning pharmacological therapies to surgical interventions.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of peripheral artery disease (PAD)
  - 3.2.1.2 Technological advancements in revascularization procedures
  - 3.2.1.3 Growing awareness and early diagnosis
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of advanced treatments
3.3 Growth potential analysis
3.4 Technology landscape
3.5 Future market trends
3.6 Regulatory landscape
3.7 Product pipeline analysis
3.8 Reimbursement scenario
3.9 Porter's analysis
3.10 GAP analysis
3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Procedures
- 5.2.1 Endovascular procedures
  - 5.2.1.1 Angioplasty
  - 5.2.1.2 Stenting
  - 5.2.1.3 Atherectomy
- 5.2.2 Surgical procedures
  - 5.2.2.1 Bypass surgery
  - 5.2.2.2 Endarterectomy
5.3 Medications
- 5.3.1 Antiplatelet drugs
- 5.3.2 Anticoagulants
- 5.3.3 Cholesterol-lowering drugs
- 5.3.4 Pain relievers
- 5.3.5 Other medications
5.4 Other treatment types

Chapter 6 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Hospitals
6.3 Ambulatory surgical centers
6.4 Other end-users

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
7.3 Europe
- 7.3.1 Germany
- 7.3.2 UK
- 7.3.3 France
- 7.3.4 Spain
- 7.3.5 Italy
- 7.3.6 Netherlands
- 7.3.7 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Australia
- 7.4.5 South Korea
- 7.4.6 Rest of Asia Pacific
7.5 Latin America
- 7.5.1 Brazil
- 7.5.2 Mexico
- 7.5.3 Argentina
- 7.5.4 Rest of Latin America
7.6 Middle East and Africa
- 7.6.1 South Africa
- 7.6.2 Saudi Arabia
- 7.6.3 UAE
- 7.6.4 Rest of Middle East and Africa